Quantcast

Elkridge-based Cel-Sci expands clinical trial sites (access required)

Posted: 2:04 pm Mon, February 25, 2013
By Daily Record Staff

Cel-Sci Corp., of Vienna, Va., and Elkridge, said its Taiwanese clinical trial partner, Orient Europharma, has added additional sites in Taiwan in Cel-Sci’s Phase III head and neck cancer clinical trial for Multikine, the company’s flagship investigational immunotherapy.

Comments

Comments are closed.

Copyright © 2012, Maryland Daily Record 11 E. Saratoga Street, Baltimore, MD, 21202 · Tel: 443-524-8100